tmem161a Antibody

TMEM161A antibodies are generated using immunogens such as recombinant protein fragments (e.g., residues 29–98 or 1–100 in humans) . Validations include:

• Western Blot: Detects bands at ~45–56 kDa in human, mouse, and rat tissues (e.g., liver, brain) .

• IHC: Staining observed in human brain, endometrial cancer, and mouse tissues .

• Immunofluorescence: Localizes TMEM161A to the cell membrane in cancer cell lines .

Recommended Dilutions

Role in Oxidative Stress and Apoptosis

• Overexpression of TMEM161A reduces oxidant-induced DNA damage and apoptosis .

• Knockdown experiments in osteoblasts (Tmem161a-deficient MC3T3-e1 cells) increased differentiation markers (Alp, Osx), suggesting TMEM161A suppresses osteoblast differentiation .

Cancer Associations

• TMEM161A is overexpressed in non-small cell lung cancer (NSCLC) and linked to MYC-driven oncogenic pathways .

• In NSCLC, TMEM161A-specific T cells cross-react with Epstein-Barr virus and E. coli antigens, implicating it in tumor immune evasion .

Bone Remodeling

• Tmem161a knockout mice exhibit increased bone mass and strength, indicating its role in inhibiting osteoblast differentiation .

Technical Considerations

• Storage: Stable at -20°C in PBS with 0.02% sodium azide and 50% glycerol .

• Antigen Retrieval: For IHC, citrate buffer (pH 6.0) or TE buffer (pH 9.0) is recommended .

• Cross-Reactivity: Some antibodies show reactivity with cow, horse, and dog samples .

Functional Implications

TMEM161A’s dual role in apoptosis regulation and cancer progression highlights its therapeutic potential. For example:

• Cancer Therapy: Targeting TMEM161A may enhance responses to EGFR/HER2 inhibitors by overcoming resistance mechanisms .

• Bone Diseases: Inhibiting TMEM161A could promote bone formation in osteoporosis .